RxDoctor Payments Data

Mariaileen Sourwine, MD

Internal Medicine · Arnold, MDNPI 1528227378

Payments from drug & device makers

What this record shows

Boehringer Ingelheim International GmbH accounts for 78.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,303 and has fallen 96.7% since, to $43 in 2025.

$1,536in general payments, 2019–2025

Across 27 payments — averaging $56.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$1K
  • Boehringer Ingelheim$77
  • Abbott$53
  • AbbVie$46
  • Pfizer$31
  • Lilly USA, LLC$22
  • plus $102 from 6 others
$570,249in research payments, 2019–2025

Across 140 payments — averaging $4073.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$552K
  • Boehringer Ingelheim International GmbH$19K

What the payments were for

  • Travel & lodging$71447%
  • Food & beverage$82253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,536 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$212,590
Medicare patients
351
Services billed
3,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase22$74,070
EliquisApixaban31$47,466
JardianceEmpagliflozin17$28,743
OzempicSemaglutide12$20,970
JanuviaSitagliptin Phosphate19$19,970
TrulicityDulaglutide18$19,154
XareltoRivaroxaban12$18,044
MounjaroTirzepatide11$17,477
Atorvastatin Calcium254$4,003
SynthroidLevothyroxine Sodium53$3,516
Rosuvastatin Calcium138$3,457
Losartan Potassium169$2,783
Levothyroxine Sodium190$2,384
Duloxetine Hcl51$2,347
Metoprolol Succinate107$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Synthroid$46$77,58675 claims
PfizerEliquis, Paxlovid$31$48,89543 claims
Lilly USA, LLCTrulicity, Mounjaro$22$36,63129 claims
Boehringer IngelheimJardiance$77$28,74317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Arnold

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →